Restoration of Transgelin 2 Expression Reverses Immune Escape in Ovarian Cancer: A Dawn for Immunotherapy

Zhiqiang Wang; Ge Lou; Mingzhu Yin

doi:10.1002/mco2.70164

MedComm ›› 2025, Vol. 6 ›› Issue (4) :e70164 DOI: 10.1002/mco2.70164

HIGHLIGHT

Restoration of Transgelin 2 Expression Reverses Immune Escape in Ovarian Cancer: A Dawn for Immunotherapy

Author information +

History +

PDF

Cite this article

Download citation ▾

Zhiqiang Wang, Ge Lou, Mingzhu Yin. Restoration of Transgelin 2 Expression Reverses Immune Escape in Ovarian Cancer: A Dawn for Immunotherapy. MedComm, 2025, 6(4): e70164 DOI:10.1002/mco2.70164

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	S. M. Hwang, D. Awasthi, J. Jeong, et al., “Transgelin 2 Guards T Cell Lipid Metabolism and Antitumour Function,” Nature 635, no. 8040 (2024): 1010-1018.

[2]	Y. Wang, Y. Wang, Y. Ren, Q. Zhang, P. Yi, and C. Cheng, “Metabolic Modulation of Immune Checkpoints and Novel Therapeutic Strategies in Cancer,” Seminars in Cancer Biology 86, no. Pt 3 (2022): 542-565.

[3]	Y. Pan, T. Tian, C. O. Park, et al., “Survival of Tissue-Resident Memory T Cells Requires Exogenous Lipid Uptake and Metabolism,” Nature 543, no. 7644 (2017): 252-256.

[4]	Q. Gu, Y. Wang, P. Yi, and C. Cheng, “Theoretical Framework and Emerging Challenges of Lipid Metabolism in Cancer,” Seminars in Cancer Biology 108 (2025): 48-70.

[5]	L. E. Kandalaft, D. Dangaj Laniti, and G. Coukos, “Immunobiology of High-grade Serous Ovarian Cancer: Lessons for Clinical Translation,” Nature Reviews Cancer 22, no. 11 (2022): 640-656.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.